{"entity":{"id":"paper-rampazzo-plasma-tert-rna-rectal-cancer-br-j-cancer-2018","kind":"paper","name":"The predictive and prognostic potential of plasma telomerase reverse transcriptase (TERT) RNA in rectal cancer patients","aka":[],"tldr":"A rectal cancer study in which tumour-associated RNA still found in plasma months after surgery marked a higher chance of the cancer progressing.","summary":"In 176 patients, those with detectable plasma TERT RNA at the later time points had a risk of disease progression 2.13 (95% CI 1.10 to 4.11) and 4.55 (95% CI 1.48 to 13.95) times higher than those with undetectable levels.","asOf":"2026-11-04","links":[{"label":"Rampazzo et al., Br J Cancer 2018","url":"https://doi.org/10.1038/bjc.2017.492"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/29449673/"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["diagnostics"],"technologies":["liquid-rna-biopsy","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["mrd"],"trials":[],"people":[],"bottlenecks":["b-subclone-attribution-residual-disease"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"British Journal of Cancer","year":2018,"doi":"10.1038/bjc.2017.492","pmid":"29449673","authors":"Rampazzo E, Del Bianco P, Bertorelle R, et al.","paperType":"translational","findings":["Detectable plasma TERT RNA after surgery: progression hazard 4.55 (95% CI 1.48 to 13.95)."],"whatItMeans":"Plasma RNA after curative treatment carries prognostic signal, but without a stated detection limit.","caveats":["Single centre; one transcript; no detection limit."],"participants":176},"route":"/key-papers/paper-rampazzo-plasma-tert-rna-rectal-cancer-br-j-cancer-2018/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"liquid-rna-biopsy","kind":"technology","name":"Liquid RNA biopsy (cell-free, vesicle and platelet RNA)","route":"/technologies/liquid-rna-biopsy/"},{"id":"mrd-testing","kind":"technology","name":"MRD / molecular residual disease testing","route":"/technologies/mrd-testing/"}],"term":[{"id":"mrd","kind":"term","name":"Minimal / molecular residual disease (MRD)","route":"/terms/mrd/"}],"bottleneck":[{"id":"b-subclone-attribution-residual-disease","kind":"bottleneck","name":"Naming which clone or phenotype is left after treatment","route":"/bottlenecks/b-subclone-attribution-residual-disease/"}],"idea":[{"id":"idea-stack-ctdna-and-tumour-rna-residual-disease","kind":"idea","name":"Read tumour RNA and tumour DNA from the same blood draw to find and type residual cancer","route":"/ideas/idea-stack-ctdna-and-tumour-rna-residual-disease/"}]}}